Search
Search
Thermo Scientific™ B·R·A·H·M·S Fast Screen™ PLUS is a core software component of an integrated prenatal screening solution that combines KRYPTOR™ analyzers, high-precision biomarker assays, and robust risk calculation algorithms. Thermo Fisher global solution supports screening for aneuploidies in first and second trimester, neural tube defects in second trimester, and preeclampsia across all trimesters of pregnancy.
B·R·A·H·M·S Fast Screen PLUS incorporates clinically developed, evidence-based algorithms, supported by scientific publications and developed using data from more than 220,000 pregnancies¹ for aneuploidy screening. This strong scientific foundation helps enable consistent individual risk assessment to support clinical decision-making.
Designed as a client–server, web-based application, B·R·A·H·M·S Fast Screen PLUS enables centralized data assessment, secure multi-user access, and real-time collaboration via a standard web browser. Flexible connectivity to one or multiple KRYPTOR instruments and laboratory information systems helps streamline workflows, reduce manual data handling, and help support efficient collaboration between laboratories and healthcare providers.
Discover the power of prenatal screening on B·R·A·H·M·S KRYPTOR analyzers
More than just a risk assessment software, experience the difference with Thermo Scientific™ B·R·A·H·M·S Fast Screen™ PLUS software
Track the status of your patients' records and quickly identify people at risk requiring prompt review
Make interaction more intuitive, enter information following suggestions or automation features to simplify tasks
Uses an engine based on a large FMF (Fetal Medicine Foundation) database to calculate risks in your population
Use a dedicated medical folder in which you can follow examinations, additional procedures and outcome of the pregnancies
| 1T Trisomy screening | Up to 4 biomarkers * |
| 2T Trisomy screening and NTD (Neural Tube Defect) | Up to 4 biomarkers ** Double, triple, quadruple test AFP for NTD |
| Preeclampsia screening in pregnancy | 1st Trimester (PlGF, PAPP-A, PlGF+PAPP-A) 2nd Trimester (PlGF and sFlt-1) 3rd Trimester (PlGF and sFlt-1) |
| Preeclampsia management with ratio | sFlt-1/PlGF in short-term prognosis and diagnosis |
* PAPP-A, Free βhCG, AFP, PlGF
** AFP, hCG/Free βhCG, uE3, Inhibin A
PAPP-A = Pregnancy-associated plasma protein A
Free βhCG = Free β human chorionic gonadotrophin
PlGF = Placental growth factor
sFlt-1 = Soluble fms-like tyrosine kinase 1
AFP = Alpha fetoprotein
hCG + β = Total human chorionic gonadotrophin
uE3 = Unconjugated estriol
Confidence in care begins with confidence in results. At Thermo Fisher, our role is to support your clinical decision.”
— Christophe Fraudeau
Vice President & General Manager, Biomarkers
Watch the full internal interview to hear Christophe share the strategic vision behind B·R·A·H·M·S Fast Screen PLUS
1. First-trimester combined screening for trisomy 21 at 7-14 weeks’ gestation
D. Wright et al., Ultrasound Obstet Gynecol, 2010
Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.
© 2026 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S and B·R·A·H·M·S Fast Screen are registered trademarks of B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. is a registered trademark of B·R·A·H·M·S GmbH.
KRYPTOR is a trademark of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific.